Table 2 Effect of oral minocycline treatment on regional translocator protein total distribution volume.

From: A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder

 

Baseline TSPO VT

Post-treatment TSPO VT

aChange in TSPO VT

Minocycline

(n = 12)

Placebo

(n = 9)

Minocycline

(n = 12)

Placebo

(n = 9)

Minocycline

(n = 12)

Placebo

(n = 9)

Effect of treatment groupb

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

F1,19

P value

PFC

12.4 (2.6)

13.6 (4.9)

11.8 (3.6)

12.5 (3.7)

−0.61 (1.7)

−1.1 (2.5)

0.28

0.60

MPFC

12.2 (2.6)

13.3 (5.1)

11.3 (3.8)

11.9 (3.7)

−0.92 (1.9)

−1.4 (2.3)

0.24

0.63

VLPFC

13.2 (2.5)

14.6 (5.0)

12.8 (4.0)

13.5 (4.2)

−0.38 (2.0)

−1.2 (2.7)

0.58

0.46

DLPFC

12.4 (2.7)

13.4 (4.7)

11.8 (3.5)

12.4 (3.7)

−0.58 (1.8)

−0.97 (2.3)

0.19

0.67

OFC

12.3 (3.4)

14.1 (4.3)

11.4 (3.9)

12.0 (3.4)

−0.83 (2.0)

−2.1 (2.4)

1.8

0.19

ACC

12.1 (3.0)

13.2 (5.0)

11.5 (4.4)

11.9 (3.3)

−0.51 (2.8)

−1.3 (2.6)

0.54

0.47

Insula

12.9 (3.0)

14.1 (4.7)

12.0 (3.9)

12.1 (3.8)

−0.93 (1.7)

−2.0 (2.2)

1.6

0.22

Temporal cortex

12.6 (3.0)

13.8 (5.0)

12.1 (4.1)

12.1 (3.4)

−0.53 (1.6)

−1.8 (2.2)

2.3

0.15

Parietal cortex

13.2 (3.0)

14.6 (5.4)

13.0 (3.9)

13.2 (4.2)

−0.21 (1.9)

−1.4 (2.3)

1.7

0.21

Occipital cortex

12.7 (3.0)

13.8 (5.1)

12.0 (4.5)

12.2 (3.8)

−0.69 (1.8)

−1.6 (2.6)

0.94

0.35

Thalamus

15.1 (3.8)

16.0 (5.3)

14.2 (5.3)

13.8 (4.4)

−0.89 (2.5)

−2.2 (3.4)

0.99

0.33

Dorsal putamen

10.9 (2.8)

11.7 (4.1)

10.2 (3.4)

10.2 (3.1)

−0.77 (1.7)

−1.5 (2.1)

0.72

0.41

Dorsal caudate

10.0 (2.4)

11.1 (3.9)

9.8 (3.2)

9.8 (3.4)

−0.25 (2.2)

−1.3 (2.7)

0.95

0.34

Ventral striatum

11.8 (3.3)

12.1 (4.8)

10.7 (3.9)

10.9 (3.2)

−1.1 (2.3)

−1.2 (2.6)

0.02

0.89

Hippocampus

11.2 (3.0)

13.1 (5.3)

11.4 (4.6)

11.6 (3.3)

0.20 (3.4)

−1.5 (5.1)

0.81

0.38

  1. ACC anterior cingulate cortex, DLPFC dorsolateral prefrontal cortex, MPFC medial prefrontal cortex, OFC orbitofrontal cortex, PFC prefrontal cortex, PET positron emission tomography, SD standard deviation, TSPO VT translocator protein total distribution volume, VLPFC ventrolateral prefrontal cortex.
  2. aChange in TSPO VT was calculated as regional TSPO VT post-treatment minus regional TSPO VT baseline. Analysis of variance comparing baseline TSPO VT values found no significant difference between groups for any regions (effects of group and genotype included, effect of group, F1,18 = 3.4–0.27, P = 0.081–0.61).
  3. bRepeated measures analysis of variance evaluating effect of group interaction on repeated measure of TSPO VT.
Back to article page